The combined use of a PS conjugated to an EGFR-targeted Nb and to nanobodies targeting vascular endothelial growth factor receptor 2 (VEGFR2), which is mainly overexpressed in the tumor vasculature, represents an alternative approach that may be able to potentiate the therapeutic response of the PDT treatment, damaging both the cancer cells and the tumor-associated vessels [217]. This evidence concerns the gene EGFR and neoplasm.